A Phase II Trial of AZD6244 (NSC 748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Trial Profile

A Phase II Trial of AZD6244 (NSC 748727) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 04 Sep 2013 Planned end date changed from 1 Jun 2009 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 04 Apr 2012 Results have been reported at AACR-2012 according to an Array BioPharma media release. Results were also summarised in the media release.
    • 04 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top